Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 科学研究和技术服务业
Company Introduction 公司是一家围绕酶、抗原、抗体等功能性蛋白及高分子有机材料进行技术研发和产品开发的生物科技企业，依托于自主建立的关键共性技术平台，先后进入了生物试剂、体外诊断业务领域，并正在进行抗体药物的研发，是国内少数同时具有自主可控上游技术开发能力和终端产品生产能力的研发创新型企业。 发行人前身诺唯赞有限系由曹林、徐晓昱、张力军、杨翔、段颖、唐波、周阳、曹生标及贾支俊共同出资设立的有限责任公司。2012年3月16日，南京市工商行政管理局玄武分局就本次设立事宜向诺唯赞有限核发《企业法人营业执照》（注册号为320102000228848）。2020年5月28日，诺唯赞召开创立大会暨2020年第一次临时股东大会并作出决议，同意诺唯赞有限以整体变更设立股份有限公司的方式，依法变更为股份有限公司。2020年6月4日，南京市市场监督管理局就本次股份公司设立事宜向诺唯赞核发变更后的《营业执照》（统一社会信用代码：91320192589435065R）。
Main Business 酶、抗原、抗体等生物制品的研发、生产和销售
Legal Representative 曹林
Top Executives
董事长：曹林
董事：唐波,胡小梅,张力军
独立董事：董伟,夏宽云,蔡江南
Top 5 Shareholder
Shareholder name Nature Holding Date
南京诺唯赞投资管理有限公司限售股40.48%30/09/2024
国寿成达（上海）健康产业股权投资中心（有限合伙）流通A股7.74%30/09/2024
杨奇流通A股5.47%30/09/2024
曹林限售股5.35%30/09/2024
南京博英维创业投资合伙企业（有限合伙）限售股3.61%30/09/2024
Company Secretary 黄金
Solicitors 北京市天元律师事务所
Auditors 立信会计师事务所（特殊普通合伙）
Tel No 025-85771179
Fax No 025-85771171
Website www.vazyme.com
Email irm@vazyme.com
Company Address
Register: 江苏省南京经济技术开发区科创路红枫科技园C1-2栋东段1-6层
Office: 江苏省南京经济技术开发区科创路红枫科技园D2栋
Listing Date 15/11/2021
Shares Capital
Shares Capital: 400,010,000
Total A Share: 400,010,000
Listed A Share: 400,010,000
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.180
DPS(RMB)* ¥ 0.100
NBV Per Share(RMB)* ¥ 10.073
Market Capitalization(RMB) 9.400B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.